In March 23rd, the national Wei Jian administration website released information about the content of Pfizer COVID-19 oral medicine in the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth), including drug names, indications and contraindications.
According to the notice on adjusting the indications of anti New Coronavirus drugs PF-07321332/ Ritonavir Tablets (Paxlovid) and so on, according to the instructions approved by the State Administration for drug control and approval of the package of NAT matwey / Ritonavir Tablets combination, the relevant contents of “PF-07321332/ Ritonavir Tablets (Paxlovid)” in the treatment of New Coronavirus pneumonia (trial version ninth) are adjusted as follows:
I. drug name
The drug name was adjusted to “combined packaging of nimatovir tablets / ritonavir tablets”.
II. Indications
The indications are adults with mild and common types within 5 days of onset and accompanied by high-risk factors for progression to severe disease.
III. usage and dosage
300mg nimatovir tablets and 100mg ritonavir tablets were taken at the same time, once every 12 hours for 5 consecutive days.
IV. contraindications
It is forbidden for patients who are allergic to the active ingredients or any excipients in this product. This product should not be used in combination with drugs that are highly dependent on CYP3A for clearance and whose elevated plasma concentration will lead to serious and / or life-threatening adverse reactions.
The notice requires that before using the drug, you should carefully read the instructions for the combined packaging of nimatovir tablets / ritonavir tablets approved by the State Drug Administration, correctly use the drug according to the indications, usage, dosage and dose specified in the instructions, be familiar with the contraindications, adverse reactions and drug interactions, and ask the patient’s drug allergy history in detail to avoid the use of the drug by patients with contraindications, Avoid using in combination with drugs prohibited by this product; All localities should do a good job in adverse reaction monitoring and reporting in strict accordance with the requirements of the measures for the administration of adverse drug reaction reporting and monitoring, so as to effectively ensure the safety of drug use.
Nimatovir tablet / ritonavir tablet (paxlovid) is an oral small molecule covid-19 virus therapeutic drug developed by Pfizer 2021 November, the product was approved by the FDA emergency authorization for high-risk adults and high-risk pediatric patients aged 12 and over weighing at least 40 kg
In February 11, 2022, the State Food and Drug Administration (FDA) was reviewed and approved by the State Food and Drug Administration for approval. It was approved by the NIM Matt Wei / Ritonavir Tablets import registration to treat patients with mild to moderate New Coronavirus pneumonia with severe risk factors.
In March 15th, the national health and Health Committee issued the “New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth)” to write Nim Matt / Ritonavir Tablets (Paxlovid) specific anti COVID-19 drugs into the diagnosis and treatment plan. applicable population is adults and adolescents (12-17 years old, weight ≥ 40kg) of light and common type within 5 days of onset and accompanied with high risk factors of progression to heavy type usage: take 300mg pf-07321332 and 100mg ritonavir at the same time, once every 12 hours for 5 consecutive days. Read the instructions carefully before use, and do not use in combination with drugs highly dependent on CYP3A for clearance, such as pethidine and ranolazine, whose elevated plasma concentration will lead to serious and / or life-threatening adverse reactions.
In March 21st, the National Health Insurance Bureau issued the circular on the effective implementation of the current epidemic prevention and control medical insurance work, and announced that it should promptly adjust the COVID-19 treatment drugs that were included in the scope of medical insurance payment. “New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth)” added the new Matt Wei / Ritonavir Tablets, which is purchased by the medical institutions according to the same price between the enterprises and the relevant departments, and the medical insurance department pays well according to the regulations.
According to China Meheco Group Co.Ltd(600056) previous announcement, at present, the first batch of 21200 boxes of nimatovir tablets / ritonavir tablets have completed the import customs formalities and are quickly transported to the front line of the national anti epidemic.
